Germany · Delayed Price · Currency is EUR Fresenius SE & Co. KGaA Earnings Call Transcripts
Fiscal Year 2026
-
Healthcare trends and portfolio transformation have positioned the company for growth, with strong performance in IV generics, nutrition, MedTech, and biopharma. Financial discipline and innovation drive double-digit EPS growth, while future plans focus on scaling core businesses and targeted capital deployment.
Fiscal Year 2025
-
Strong 2025 results with 7% organic revenue and 12% core EPS growth, robust cash flow, and a 5% dividend increase. 2026 guidance targets 4%-7% organic revenue growth and 5%-10% core EPS growth, with continued investment in innovation and digitalization.
-
Management outlined a bold strategy to double biopharma revenue and portfolio by 2030, targeting a 20% EBIT margin through innovation, cost leadership, and global commercial expansion. Strong financial performance, a robust pipeline, and significant investments in R&D and manufacturing underpin confidence in long-term growth and value creation.
-
Raised EBIT growth guidance to 4%-8% at constant currency, driven by strong execution, 14% EPS growth, and robust performance in Kabi and Helios. Continued deleveraging, targeted investments, and innovation underpin positive outlook into 2026.
-
Strong H1 2025 results with 8% core EPS growth and upgraded revenue guidance to 5-7%, driven by robust performance at Kabi and Helios. Key launches in biosimilars, disciplined capital allocation, and resilience amid macroeconomic and FX headwinds support a positive outlook.
-
The AGM highlighted strong financial growth, significant debt reduction, and a doubling of share price since 2022. Strategic initiatives include the Rejuvenate phase, investments in innovation, and a new dividend policy. Key risks such as geopolitical uncertainty and workforce shortages were addressed.
-
Q1 2025 saw strong organic revenue and EPS growth, with CABI and Helios delivering robust performance. Strategic simplification, deleveraging, and successful biosimilar launches support full-year guidance, despite expected Q2 headwinds from China and FX.
-
A comprehensive transformation has streamlined operations, improved financials, and positioned the business for growth through innovation and new product launches in 2025. Biopharma is now profitable, with Tyenne and other biosimilars set to drive further gains, while disciplined capital allocation and resumed dividends support shareholder value.
Fiscal Year 2024
-
Delivered strong 2024 results with high single-digit organic revenue and double-digit EBIT growth, driven by Kabi and Biopharma. 2025 guidance targets 4%-6% revenue and 3%-7% EBIT growth, with continued margin expansion and resumed dividends.
-
Q3 2024 saw strong organic revenue and earnings growth, driven by Kabi and Helios, with robust cash flow and improved leverage. Upgraded guidance reflects confidence despite headwinds from China, lower biopharma milestone payments, and the end of energy relief funding.
-
Strong Q2 and H1 2024 results with 8% organic revenue growth, 15% EBIT increase, and robust cash flow drove leverage down to target levels. Kabi and Helios segments excelled, while cost savings and innovation supported margin expansion. China remains a headwind.
-
The group has raised its financial ambitions, targeting 4%-6% organic revenue growth and a 10%-12% margin by 2027, driven by operational excellence, digital transformation, and strong market positions in Germany and Spain. Regulatory changes and portfolio optimization are seen as opportunities for further growth and efficiency.